Company Overview
NRx Pharmaceuticals, Inc. operates as a clinical-stage bio-pharmaceutical entity focused on the development of novel therapeutics designed to treat central nervous system disorders, specifically targeting conditions such as suicidal depression, post-traumatic stress disorder, and chronic pain. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself in a market characterized by high regulatory hurdles and significant research and development expenditures. As of the latest available data, the firm holds a market capitalization of $72.42M and reports a trailing twelve-month revenue of $1.23M, with no specific employee count disclosed in current records. These financial metrics indicate that NRx Pharmaceuticals is a small-cap entity with limited revenue generation relative to its market valuation, suggesting a company that relies heavily on future product approvals and clinical trial outcomes rather than established commercial sales to drive its valuation.
Financial Health
The company reported a trailing twelve-month revenue of $1.23M, yet this revenue figure masks a substantial net income loss of $-28,622,000, while EBITDA stands at $-16,118,000. The significant disparity between the modest revenue of $1.23M and the net income loss of $-28,622,000 reveals a cost structure where operating expenses, likely driven by clinical trial costs and R&D activities, vastly outweigh current sales income. Free cash flow is recorded at $-805,875, which indicates that the company is consuming cash reserves to fund its operations and development pipeline rather than generating liquidity from current business activities. Analyzing the profit margins shows a gross margin of 58.8%, an operating margin of -467.3%, and a profit margin of 0.0%, where the negative operating margin signifies that operating expenses are more than four times the revenue base. On the balance sheet, the company holds $7.80M in cash against $631,000 in debt, resulting in a debt-to-equity ratio that is not applicable, suggesting a leveraged position in terms of equity but a relatively low absolute debt load. The current ratio stands at 0.31, indicating that current assets are less than one-third of current liabilities, which points to potential short-term liquidity constraints. Return on Equity is not applicable, while Return on Assets is -121.8%, revealing that the company's asset base is generating negative returns relative to its total asset value.
Valuation Assessment
Valuation metrics for NRx Pharmaceuticals present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of 16.85, implying that the market is pricing in expected future earnings recovery despite current losses. The price-to-book ratio is listed at -4.35, a negative figure that indicates the market is valuing the company's equity at a significant discount relative to its book value, often seen in loss-making biotech firms. Alternative valuation measures such as the price-to-sales ratio of 59.12 and an EV/EBITDA of -4.04 suggest that investors are placing a premium on the company's sales potential and intellectual property despite the lack of profitability. Price action over the last year shows a 52-week high of $3.84 and a 52-week low of $1.58, placing the current trading price within a range that reflects high volatility. The beta value of 1.99 indicates that the stock's price volatility is nearly double that of the broader market, exposing investors to significantly higher risk during market fluctuations.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings versus revenue expansion rates in the current period. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm does not distribute cash to shareholders but instead retains all earnings to reinvest into its clinical development programs. This approach aligns with the typical lifecycle of a clinical-stage biopharmaceutical company, where capital is prioritized for research and development rather than income distribution. The overall growth and income profile is defined by the absence of current profitability and dividend income, relying entirely on the potential future commercialization of lead drug candidates like NRX-101 to drive value creation for shareholders.